Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a daratumumab-based triplet2 Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care, and with a new streamlined REMS … [Read more…]
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc., (www.sydnexis.com), a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the New Drug Application (NDA) for SYD-101, a proprietary 0.01% atropine formulation developed with enhanced ocular delivery characteristics and room-temperature stability to … [Read more…]
First two monotherapy dose levels (400 mg QD and 600 mg QD) cleared, with no dose-limiting toxicities reported Promising anti-tumor activity observed in patients with various solid tumors, including advanced pancreatic ductal adenocarcinoma No nausea, vomiting, or diarrhea greater than Grade 1 was observed Enrollment initiated for VS-7375 in combination with cetuximab in patients with … [Read more…]
New initiative creates pathways to employment and connection for individuals with intellectual and developmental disabilities across Belmont Village communities. HOUSTON–(BUSINESS WIRE)–Belmont Village Senior Living is excited to announce its national employment partnership with Best Buddies International, a nonprofit organization dedicated to creating opportunities for one-to-one friendships, integrated employment, leadership development, inclusive living, and family support … [Read more…]
Strategically established life sciences air corridor will link Shannon, Ireland, and Wilmington, North Carolina, marking the first fully dedicated, temperature-controlled network of its kind SHANNON, Ireland & WILMINGTON, N.C.–(BUSINESS WIRE)–Frontier Scientific Solutions (“Frontier”) today announced the initial flight schedule for its nonstop, temperature‑controlled air corridor between Shannon Airport (SNN) and Wilmington International Airport (ILM). Developed … [Read more…]
NANTES, France & TOKYO–(BUSINESS WIRE)–Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, and the Tokyo Metropolitan Institute of Medical Science (TMIMS), today announce their collaboration for the development of a new mpox vaccine using a live-attenuated vaccine. Mpox is a viral illness caused by the monkeypox virus. It … [Read more…]
Collaboration will leverage AGC Biologics’ commercial manufacturing experience and proven platforms to seek regulatory approval for a therapy treating the rare immunodeficiency disorder, ADA-SCID. MILAN–(BUSINESS WIRE)–#Biotech–AGC Biologics, your friendly CDMO expert, today announced an agreement with Rarity PBC to provide comprehensive development and Good Manufacturing Practice (GMP) manufacturing for Rarity’s gene therapy, RDP-101, for Adenosine … [Read more…]
Ad hoc announcement pursuant to Art. 53 LR ZUG, Switzerland–(BUSINESS WIRE)–Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commercial and innovation momentum across its portfolio. Record net sales of 3.737 billion USD for the first … [Read more…]
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–Scienza Health, a pioneer in AI-powered healthcare, and Samsung announce a collaboration delivering advanced patient screening, engagement, and monitoring through Galaxy smartwatches, phones, and tablets. Scienza’s digitalhumanOS™ and ERaaS™ platform uses ambient speech analysis and real-time biometric data to support cognitive and neurological health screenings, automate clinical workflows, and improve patient and … [Read more…]
NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17th, 2025. Management will participate in a Fireside Chat at 10:40 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com. An … [Read more…]
